The CCO role is evolving, argue John Archer and Roger Longman, as applicants must challenge entrenched views and manage a growing set of stakeholders with creativity

Plus:

Eylea remains market leader as Roche’s grows its share of AMD pie; biosimilars still a rounding error

Also in BioCentury’s Clinical Report: Cartesian’s autoimmune CAR T durability, Roivant’s miss, Novocure’s pancreatic cancer data, and more

Samsara-backed start-up launched by former Genentech colleagues picks AlloVir as vehicle to reach NASDAQ

Back to School 2023 case study: Regeneron’s is a story of leveraging platform technology to repeatedly generate high-value assets

Commercial success will depend on physician willingness to switch to high-dose aflibercept in increasingly competitive market

First risk-sharing investment since VC’s takeout will position strategic entity Launch to advise Australian biotech as it navigates Phase III with up to $260M

Plus Megaround for Sironax, and updates from Eleven, Roche, Axcella, Phathom, and more

Plus Transition’s $50M A round, Centessa’s killed kidney program and updates from Centessa, Aeglea, Immunic and more